Table 2. Summary of baseline criteria in the included studies (n = 8).
F: female; M: male; FO: fish oil; OO: olive oil; SD: standard deviation; SO: safflower oil
| Study | Sample size | Age (years), mean ± SD | Gender (M:F) | |||
| Omega-3 | Control | Omega-3 | Control | Omega-3 | Control | |
| Peck et al. [12,13] | FO: 8 | OO: 9; SO: 8 | 54.8 ± 16.2 | OO: 45.6 ± 17.4; SO: 49.5 ± 17.2 | 5:3 | OO: 4:5; SO: 4:4 |
| Begum et al. [31] | FO: 12 | SO: 10 | 61.2 ± 19.42 | 49.25 ± 18.12 | 7:3 | 6:6 |
| Ghanei et al. [32] | 11 | Placebo: 11 | 59.90 ± 14.82 | 53.09 ± 13.08 | 72%:28% | 54%:46% |
| Lahiji et al. [33] | 20 | Placebo: 20 | 62.1 ± 11.6 | 61.9 ± 10.8 | 9:11 | 10:10 |
| Shayanpour et al. [34] | 32 | Placebo: 32 | 51.91 ± 6.586 | 56.25 ± 8.865 | 27:5 | 23:9 |
| Heydarbaki et al. [35] | 26 | Cetirizine: 26 | 61.34 ± 15.7 | 57.7%:42.3% | ||
| Forouhari et al. [36] | 17 | Placebo: 16 | 59.00 ± 13.56 | 51.25 ± 15.85 | 70.6:29.4 | 68.8:31.2 |
| Rafieipoor et al. [37] | 58 | Placebo: 54 | 61.17 ± 12.35 | 55.33 ± 12.6 | 30:28 | 37:17 |